Deliver Your News to the World

Stem Cell Innovations officially opened its European R&D facility in Leiden, The Netherlands


June 1, 2006

Leiden, The Netherlands – Stem Cell Innovations, Inc. (SCLL.OB) announced yesterday that the Company has opened a new R&D facility to commercialise their proprietary platform of human pluripotent stem cells (PCs™) in Europe. The facility is based in Leiden, the Netherlands and encompasses 1,000 m2 of state-of–the-art research laboratories.

“Establishing a site in Europe is part of SCI’s strategy to become a global leading player in the rapidly evolving stem cell field”, said CEO Dr. James Kelly.
“We are now in a much better position to efficiently serve the growing European market for high quality drug discovery tools, including complex disease models that can be alternatives for animal testing. Moreover a site in the Netherlands will allow high-level interactions with EU leaders in cell-therapeutics, both from Industry and Academia”.

The Company recently disclosed it has produced multiple lines of human pluripotent stem cells. These PC lines are able to maintain their undifferentiated state and normal chromosome complement. More importantly, the cells can be efficiently cultured in tissue culture plates without the use of feeder layers (xenofree).

The European site of SCI will be led by Dr. Helmuth van Es (CSO) and Ivo Piest (Senior Director Business & Corporate Development), both members of the Company’s global management team.

Contact Europe:
Ivo Piest - Senior Director Business & Corporate Development
M +31 6 29 096 379, T +31 71 711 8000
Ellen de Waal - PR & Corporate Communications
M +31 6 54 711 703, T +31 70 356 1534

● About Stem Cell Innovations, Inc.
Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies, which is based in Houston, Texas, is a cell biology company. It utilizes its proprietary C3A human liver cell line in the field of drug discovery and toxicology testing and is also engaged in the development and production of its proprietary PC™ pluripotent stem cells. These human cell-based disease models create a platform for the discovery, testing
and development of all therapeutic modalities including small molecules, cell-based therapeutics, small interfering RNAs and antibodies.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.